bg-img9.jpg

ISCT 2017: Optimizing your Advanced Therapy Supply Chain

Posted by Simon Ellison on Apr 19, 2017 9:55:00 AM

Ensuring that your therapy is delivered to the intended patient at the correct time and temperature are all key components for commercialization. To accomplish this, an optimized supply chain is imperative. Fisher BioServices understands these important factors and offers our global infrastructure and services to support the commercialization of advanced therapies.ISCT2017.jpg

To help us work towards this common goal, we are pleased to announce our participation as a gold sponsor at the International Society for Cellular Therapy (ISCT) Annual Meeting in London. Since 2017 marks the 25th anniversary of ISCT, the exciting milestone is reflected in the meeting agenda which showcases how the field has progressed in pre-clinical research, clinical trials, and ultimately in delivering new therapies to patients around the world.

From booth #200 we will showcase our comprehensive advanced therapy development offering, highlighting products and services which support the entirety of the workflow as well as an exciting virtual reality experience!  We are also hosting several insightful sessions:

A Defined System for Commercial Scale CAR-T Production May 4th, 12:30PM
Although the cell and gene therapy industry is primed to produce viral vectors on a scale suitable for clinical supply of orphan indications, process development scientists are still working toward generating industrialized platform technologies that will enable efficient, simple, and inexpensive production of biologically active viral vectors for large-scale commercial manufacturing. This panel will discuss how scalable systems can be used for efficient and cost-effective CAR T production to advance your CAR T-cell therapy to commercial scale.
Moderator:  Eric Roos, Strategic Alliances Leader, Cell Therapy, Thermo Fisher Scientific, USA

Panelists:

Angel Varela-Rohena
Sr. Manager
Bioproduction Division
Thermo Fisher Scientific, USA

James L. Riley, Ph.D.
Research Associate Professor of Microbiology
University of Pennsylvania, USA

Dr. Xavier de Mollerat du Jeu
Director R&D
Life Science Group
Thermo Fisher Scientific, USA

Industrializing the Vein-to-Vein Supply Chain May 4th, 3:30PM
Moderator:  Jacqueline Barry, Ph.D., Cell and Gene Therapy Catapult, United Kingdom
Panelists:

Simon Ellison, MBA
Fisher BioServices
United Kingdom

Chris Creasey, Ph.D.
Asymptote Ltd.
United Kingdom

Peter Olagunju, MBA
bluebird bio
United States

Industrialization with the Patient in Mind, May 5th, 1:45PM
Cell and gene companies have moved through the translational research phase and evolved past development into viable, market ready organizations. This has been, and continues to be, a rocky road. However the evidence shows that success is reliant on creating a therapy that can treat patients beyond a clinical trial. This session will draw on learning experiences from other industries and combine them with examples from the cell and gene therapy industry to highlight the criticality of maintaining a patient focus throughout cell therapy clinical and commercial development.
Moderator:  Simon Ellison, MBA, Senior Manager, Advanced Therapies, Fisher BioServices, UK 

Panelists:

Olav Hellebø, MBA
CEO
ReNeuron
United Kingdom

Marc Turner, MBChB, PhD, MBA
Medical Director
Scottish National Blood Transfusion Service
Scotland

Kurt Gunter, MD
Chief Medical Officer
Cell Medica Inc
USA

Sven Kili, MD
VP, Head of Gene Therapy Development
GSK
United Kingdom

Poster Sessions

  • Novel Media Supplement Increases CD8+ T cell Frequencies During T cell Therapy Manufacturing, Mansour, Sarya
  • New Dynabeads™Treg CD3/CD28 and animal origin-free, serum-free media for Regulatory T cell Activation and Expansion to be used in Clinical Applications, Bernstroem, Kerstin
  • A cGMP Sendai viral reprogramming kit for generation of clinical-grade iPSC, MacArthur, Chad

We look forward to sharing our solutions with you and discussing the latest breakthroughs in cell therapy research and development. To learn more about our advanced therapy solutions, we encourage your to read our blog or download our eBook Commercially Successful Cell Therapies: Navigating the Ultra Cold Chain Distribution Minefield.
ebookcoverdesign2.png
Download eBook